In the latest trading session, Teladoc (TDOC - Free Report) closed at $152.87, marking a -0.29% move from the previous day. This move lagged the S&P 500's daily gain of 0.2%.
Prior to today's trading, shares of the telehealth services provider had lost 4.47% over the past month. This has lagged the Medical sector's loss of 3.49% and the S&P 500's gain of 3.28% in that time.
Investors will be hoping for strength from TDOC as it approaches its next earnings release, which is expected to be July 27, 2021. On that day, TDOC is projected to report earnings of -$0.59 per share, which would represent a year-over-year decline of 73.53%. Our most recent consensus estimate is calling for quarterly revenue of $500.97 million, up 107.85% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$3.03 per share and revenue of $2.01 billion. These totals would mark changes of -168.14% and +83.76%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for TDOC. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.39% lower within the past month. TDOC is currently sporting a Zacks Rank of #4 (Sell).
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
In the latest trading session, Teladoc (TDOC - Free Report) closed at $152.87, marking a -0.29% move from the previous day. This move lagged the S&P 500's daily gain of 0.2%.
Prior to today's trading, shares of the telehealth services provider had lost 4.47% over the past month. This has lagged the Medical sector's loss of 3.49% and the S&P 500's gain of 3.28% in that time.
Investors will be hoping for strength from TDOC as it approaches its next earnings release, which is expected to be July 27, 2021. On that day, TDOC is projected to report earnings of -$0.59 per share, which would represent a year-over-year decline of 73.53%. Our most recent consensus estimate is calling for quarterly revenue of $500.97 million, up 107.85% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$3.03 per share and revenue of $2.01 billion. These totals would mark changes of -168.14% and +83.76%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for TDOC. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.39% lower within the past month. TDOC is currently sporting a Zacks Rank of #4 (Sell).
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TDOC - FREE